Boston Family Office LLC Cuts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Boston Family Office LLC cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 18,997 shares of the medical equipment provider’s stock after selling 437 shares during the quarter. Boston Family Office LLC’s holdings in Hologic were worth $1,547,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. 1832 Asset Management L.P. lifted its holdings in Hologic by 6.2% in the first quarter. 1832 Asset Management L.P. now owns 27,417 shares of the medical equipment provider’s stock worth $2,137,000 after buying an additional 1,597 shares during the period. BOKF NA grew its stake in Hologic by 6.4% in the first quarter. BOKF NA now owns 10,508 shares of the medical equipment provider’s stock worth $800,000 after purchasing an additional 631 shares during the period. Mount Yale Investment Advisors LLC raised its holdings in Hologic by 123.4% in the first quarter. Mount Yale Investment Advisors LLC now owns 8,982 shares of the medical equipment provider’s stock worth $700,000 after purchasing an additional 4,961 shares in the last quarter. SVB Wealth LLC lifted its position in Hologic by 2.2% during the first quarter. SVB Wealth LLC now owns 19,632 shares of the medical equipment provider’s stock valued at $1,531,000 after buying an additional 428 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Hologic by 29.5% during the 1st quarter. Janus Henderson Group PLC now owns 99,707 shares of the medical equipment provider’s stock valued at $7,773,000 after buying an additional 22,732 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Stephens restated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. UBS Group upped their price target on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada lifted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Finally, Mizuho reduced their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Trading Up 0.3 %

NASDAQ:HOLX opened at $78.97 on Monday. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The business has a fifty day moving average price of $80.44 and a 200-day moving average price of $78.35. The firm has a market capitalization of $18.34 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.